Clinical Trials Browser

Phase 2 × Squamous Cell Carcinoma of Head and Neck × spartalizumab × Clear all

NCT04080804 2026-04-22

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Phase 2 Active not recruiting

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06437522 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 2 Recruiting

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

184 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06170710 2023-12-14

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Phase 2 Recruiting

173 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05213884 2023-05-06

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Phase 2 Recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck